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Open access unBackground and purpose: To test whether the interval between diagnostic and therapeutic FDG-PET-scan-
ning is associated with early tumour progression.
Material and methods: All patients (n = 45) underwent two PET scans, one for staging (‘baseline PET’)
using an HR+ positron camera or PET/CT-scanner and one for radiotherapy planning (‘therapeutic PET’)
using a PET/CT-scanner.
Material and methods: All images were reviewed in random order by an experienced nuclear physician. If
there were any discrepancies, the images were also compared directly. SUVmax, tumour length, lymph
node metastases and distant metastases were assessed.
Results: The median time between the PET scans was 22 days (range: 8–49). The SUVmax increased (>10%)
(19 patients, 42%) or decreased (11 patients, 24%). Fourteen patients (31%) showed tumour length pro-
gression (>1 cm). TNM progression was found in 12 patients (27%), with newly detected mediastinal
nodes (N) in eight patients (18%) and newly detected distant metastases (M) in six patients (13%). No sig-
niﬁcant prognostic factors were found. However, a trend was noted towards TNM progression for the
type of PET-camera (p = 0.05, 95% CI 0.01–0.66) and for the interval between the PET scans (p = 0.09,
95% CI 0.9 to 12.5).
Conclusion: This study suggests rapid oesophageal tumour progression. Therefore, the interval between
relevant imaging and start of the radiotherapy should be minimized. Furthermore, ‘state of the art’ PET
scanners should be used.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 106 (2013) 283–287In the last two decades, major efforts have been made to
improve survival by exploring new and emerging treatment
strategies in oesophageal carcinoma [1,2]. Neo-adjuvant chemora-
diotherapy (CRT) followed by surgery has been shown to signiﬁ-
cantly improve the survival rates as compared to surgery alone
[3]. However, despite the introduction of these multimodality
treatment strategies into routine clinical practice, treatment fail-
ure, including both loco-regional recurrences and distant metasta-
ses are frequently observed, even after complete local tumour
response.
In oesophageal cancer, TNM-stage, standardized uptake value
(SUV) and tumour length are important prognostic factors for over-
all survival. More speciﬁcally, small sized tumours with low SUV
values without lymph node metastases are associated with better
overall survival. Although tumour length is not included in the cur-
rent TNM staging system, the association between tumour lengthdiation Oncology, University
roningen, The Netherlands.
der CC BY-NC-ND license.and outcome in terms of loco-regional tumour control and overall
survival has been well recognized [4,5].
Tumour progression can be identiﬁed by an increased SUV on
FDG-PET. A high SUV is commonly associated with tumour aggres-
siveness as expressed by an increased tumour length and nodal
involvement [6]. As tumour progression growth continues during
both the diagnostic and the preparation phase for irradiation, it
is worthwhile to examine the clinical impact of tumour progres-
sion in this time interval. The routine introduction of an increased
number of sophisticated diagnostic procedures to improve the
staging and accuracy of target deﬁnition and delineation for radio-
therapy has certainly led to an improvement of quality, but often at
the expense of increased time required to perform all these proce-
dures. Moureau-Zabotto et al. [7] found new distant metastases on
FDG-PET/CT-scans made for radiotherapy treatment planning in 6%
of the patients which consequently lead to a change of treatment
strategy from curative to palliative intent.
Therefore, in the current study, we tested the hypothesis that
the time interval between the diagnostic and therapeutic FDG-
PET-scan performed for radiotherapy treatment planning is associ-
ated with tumour progression in terms of increased SUV-values
284 Early oesophageal tumour progressionand tumour lengths, newly diagnosed pathologic lymph nodes and
distant metastases,Methods and materials
Patients
The study population was composed of patients who met the
following eligibility criteria: histologically conﬁrmed oesophageal
cancer (adeno- or squamous cell carcinoma); stage T2-T4a/N0 or
T1-T4a/N1-N3, M0; selected for curative (neo-adjuvant) CRT, and
no previous treatment or active infection.
All patients were staged according to the 7th edition of the
TNM-system of the Union International Contre le Cancer (UICC)
[8], based on the following procedures: physical examination,
endoscopic ultrasonography (EUS), cervical/thoracic/abdominal
CT, and whole body FDG-PET. Fine needle aspiration biopsy (FNAB)
or other additional investigations were carried out only when indi-
cated. After the collection of all diagnostic information, the pa-
tients were discussed in a multidisciplinary tumour board.
All patients were included in a prospective trial to assess the
impact of a planning-PET/CT compared to the standard planning-
CT on the delineation of target volumes for curative (CH-)RT of
oesophageal cancer. For this purpose, all patients underwent a sec-
ond, i.e. a research, FDG-PET(/CT)-scan for future radiotherapy
treatment planning. This study was approved by the local ethics
committee and all patients provided written informed consent.Table 1
Patient and tumour characteristics.
Characteristics n = 45 (%)
Gender
Male 33 (73)
Female 12 (27)
Age (years)
Median (range) 63 (41–85)
Histology
AC 34 (76)
SC 11 (24)
Tumour localization
High 1 (2)
Mid 3 (7)
Distal/GEJ 41 (91)
Clinical stage
T2N0M0 4 (9)
T2N1M0 4 (9)
T3N0M0 4 (9)
T3N1M0 12 (27)
T3N2M0 11 (24)
T3N3M0 4 (9)
T4aN0M0 2 (4)
T4aN1M0 2 (4)
T4aN2M0 2 (4)Imaging
Staging FDG-PET(/CT)-scans were performed after the initial
diagnosis of the primary oesophageal tumour. These FDG-PET-
scans will be referred to as ‘baseline PET’. For radiotherapy treat-
ment planning, a second PET/CT scan was performed in treatment
position over a limited ﬁeld of view within 2 weeks after referral to
the department of Radiation Oncology, and will be referred to as
‘therapeutic PET’.
The baseline PET scans were performed using an ECAT HR + PET
camera (Siemens/CTI, Knoxville, TN, USA) or an integrated PET/CT
scanner (Biograph mCT 4-64 PET/CT, Siemens, Knoxville, TN,
USA). The therapeutic PET images were all acquired using the inte-
grated PET/CT scanner. All PET-scans were reconstructed according
to a validated and standardized protocol to minimize the variabil-
ity of SUV measures due to the use of different PET-cameras [9,10].
Serum glucose levels were measured after the patients had fas-
tened for at least 4 h. Depending on body weight (5 MBq/kg for
HR+ and 3 MBq/kg for integrated PET/CT), a median dose of
378 MBq FDG (range 170–618) was administered intravenously.
Emission scans were obtained 60 min after the injection of FDG
and were performed for 5 min per bed position on the HR+ and
2–3 min per bed position on the integrated PET/CT. The baseline
PET included the skull to mid femur. For the therapeutic PET the
neck, thorax and the upper abdomen, including the liver, were
included.
All images were reviewed in random order and without knowl-
edge of the patient’s details by an experienced nuclear physician
(JP). For quantitative analysis of the FDG uptake, the maximum
standardized uptake value (SUVmax) based on body weight and cor-
rected for serum glucose was used [10,11]. Serum glucose levels
were measured before each PET examination, using a calibrated
glucose metre.
For further analyses, the following features were used: visual
tumour length, tumour length using 70% of the SUVmax (SUV70%),
and visual interpretation of lymph nodes involvement and/or the
presence of distant metastases.If there were any discrepancies after the independent scoring
between the two FDG-PET scans of one individual patient, the
images were also compared directly in order to verify the origin
of the discrepancies.Follow up
Histo[cyto]pathological conﬁrmation of the tumour progression
as detected by the therapeutic FDG-PET[/CT] was not performed,
since both PET-scans were reviewed and compared during or after
the neo-adjuvant chemoradiation. Therefore, we compared the
overall survival for the patients with and without TNM-progres-
sion. Routine follow up was performed every 3 months in the ﬁrst
year and 6 months in the second year, followed by a yearly control.
In the ﬁrst 2 years, a CT-scan of the thorax and abdomen was part
of this follow up for non-metastasized patients.Statistical analysis
Univariate analysis was carried out to assess the association be-
tween the interval between prognostic determinants and TNM
progression, tumour length progression or an increased SUV. An
independent t-test was performed for dichotomised variables,
while a chi-square test was used for continuous variables.
Overall survival time was calculated from the last day of exter-
nal radiotherapy, according to the Kaplan–Meier method. Survival
curves were compared using the log rank test. To perform these
calculations, SPSS version 18.0 was used.Results
Between March 2009 and June 2011, a total of 45 patients were
included, with a median age of 64 years (range: 41–85 years). Most
tumours were adenocarcinoma (76%) and located at the distal
oesophagus (91%). Patients and tumour characteristics are listed
in Table 1. All patients underwent a second FDG-PET/CT scan,
which was performed after a median interval of 22 days (range:
8–49 days) after baseline PET.
The therapeutic FDG-PET/CT-scan revealed 18 new pathologic
lymph nodes, which resulted in a changed N-stage in eight patients
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interval between the 2 PET-scans were not signiﬁcant prognostic
factors for the ﬁnding of new pathologic lymph nodes.
Two lymph nodes, that were suspicious at baseline PET, were no
longer visible at the therapeutic FDG-PET/CT, suggesting a non-
malignant origin. In one of these patients, the N-status changed
from N1 to N0. In this patient, the FDG-uptake in a lymph node
at the minor curvature with an initial SUV of 2.9 was no longer ob-
served at the therapeutic FDG-PET/CT.
All patients were initially staged as M0 on their baseline FDG-
PET(/CT). However, new distant metastases became manifest in
six patients (13%), making them ineligible for curative treatment.
Overall, a total of 12 patients (27%) showed tumour progression
in terms of a worse TNM-stage (Fig. 1). There characteristics are
listed in Table 2. We found no signiﬁcant prognostic factors for
TNM progression. However, a trend was noted towards TNM pro-
gression for the type of PET-camera used (p = 0.05, 95% CI 0.01–
0.66) and for the interval between the two PET scans (p = 0.09,
95% CI 0.9 to 2.5).
At visual interpretation 14 patients (31%) showed progression
in tumour length with >1 cm. A tumour length reduction was
found in two patients (4%). For the other 29 patients (65%), the tu-
mour length at the baseline FDG-PET was similar to the tumour
length at the therapeutic FDG–PET/CT. Univariate analyses showed
no signiﬁcant prognostic factors for tumour length progression.
The corrected SUVmax of the primary tumour increased by more
than 10% in 19 patients (42%), while a decrease of the corrected
SUVmax by more than 10% was seen 11 patients (24%). The mean
and median corrected SUVmax of the primary tumour of the base-
line PET and the second PET were comparable.
The SUVmax and the length of the primary tumour at the base-
line PET images were signiﬁcant prognostic factors for an increase
of the SUV at the second PET. Patients with an increased SUV hadFig. 1. Lymph node progression was found within an interval of 31 days between the d
PET/CT scanner.smaller tumours (38 vs 50 mm) with a lower SUV (11 vs 16) at
the baseline PET.
The newly diagnosed pathologic lymph nodes at the second
PET-scan had a median SUV of 4.5 (range 2.6–9.9). Nine patients
showed an increased SUV (mean increase 2.9) of previously diag-
nosed lymph nodes. Six of them also had an increased SUVmax of
the primary tumour. However, two patients showed a decrease
of the SUVmax of the primary tumour.
Three patients showed a decreased SUV of pathologic lymph
nodes diagnosed at the baseline PET. In all these patients we found
more than 10% increase of the SUV of the primary tumour and/or
an increased number of pathologic lymph nodes. In one patient
the SUVmax remained the same.
At the time of analysis, 15 patients (33.3%) had died within 2–
22 months after the start of treatment. The other 30 patients were
still alive (66.7%) at a median follow up time of 14 months. The 1-,
2- and 3-year overall survival (OS) rates were 84%, 72%, and 59%,
respectively. The mean survival was 18 months (95% CI; 15–
21 months).
TNM progression between the two PET-scans and an increased
number of pathologic lymph nodes were signiﬁcant prognostic fac-
tors for OS (Table 1). For the TNM-progression group the mean sur-
vival was 12 months (95% CI; 6–17 months) as compared to
20 months for the group without TNM-progression (95% CI; 17–
23 months).
The causes of death were not signiﬁcantly different between the
group with or without TNM progression (p = 0.35). In the group
with TNM-progression two patients (17%) died post-operatively.
The other ﬁve patients (42%) died of progressive disease. For pa-
tients without TNM-progression the causes of death were in hospi-
tal in two patients (6%), intercurrent disease in one patient (3%)
and progressive disease in ﬁve patients (15%). Another patient
(3%) died because of pulmonary complications and decompensatioiagnostic and therapeutic PET scans, which were both performed on the integrated
Table 2
Characteristics of patients with TNM progression.
No. Age Sex Histology Diagnostic Time interval
(days)
DSUVmax
corrected
D Number of
lymph nodes
Therapeutic
SUVmax
corrected
Tumour
length (cm)
cN cM Type of
camera
cN cM Location M
19 64 Male PCC 9.4 c 2 0 Integrated
PET
29 1.3 -1 1 1 Pleural left
30 68 Male AC 11.1 7.0 1 0 HR+ 33 1.7 0 1 1 Thoracic
vertebra
46 65 Female PCC 13.6 6.2 1 0 HR+ 49 0.7 0 1 1 Lung(2x)
49 63 Male AC 11.3 3.2 0 0 Integrated
PET
18 1.4 1 1 0 –
50 70 Male AC 16.0 4.8 2 0 HR+ 29 6.8 0 2 1 Diffuse
hepatogenic
56 75 Male AC 12.9 10 2 0 Integrated
PET
44 8.3 1 2 1 Lung LBK
68 80 Male AC 42.1 5.4 1 0 Integrated
PET
31 8.7 4 3 0 –
74 62 Male AC 28.6 6.4 0 0 HR+ 14 3.0 2 1 1 Lung right
72 66 Male AC 13.7 4.0 0 0 HR+ 32 1.7 1 1 0 –
51 63 Female AC 46.2 5.7 1 0 HR+ 42 17.9 1 1 0 –
41 64 Male PCC 15.5 4.6 0 0 HR+ 15 2.3 0 0 0 –
80 70 Male AC 14.1 5.5 0 0 HR+ 20 4.1 1 1 0
286 Early oesophageal tumour progressioncordis within 90 days after surgical resection, which might have
been treatment related as well.Discussion
In the present study, tumour progression between baseline
FDG-PET and a research/therapeutic FDG-PET/CT, in terms of in-
creased tumour length and/or more advanced TNM-stage, was
found in a substantial portion of the patients (31% and 27%, respec-
tively), despite the relatively short interval between the two PET
scans (median 22 days).
Studies on repeated PET-CT imaging prior to the neo-adjuvant
treatment are scarce. However, several studies reported on post-
neoadjuvant distant metastases, with incidences varying from 8%
to 17% [12–16]. Interval distant metastases may be explained by
tumour progression during and/or after neo-adjuvant treatment.
In the two largest studies by Bruzzi et al. and Blom et al., interval
distant metastases were described in 8% of the patients. All of these
patients were diagnosed with distal adenocarcinomas with posi-
tive nodal stages, suggesting lymph node involvement to be a risk
factor for the development of interval metastases. Progression of
the metastatic tumour burden prior to the treatment might also
explain the post-neoadjuvantly detected metastases, since the ex-
pected systemic effect of the chemotherapy regimen used for the
neoadjuvant chemoradiation seems limited [3].
In the present study, newly detected pathologic lymph nodes or
distant metastases were found in pre-treatment in 27% of the pa-
tients, after comparison of the 2 PET-scans. However, progression
over time seemed not the only factor for the detection of pre-treat-
ment tumour progression. There was also a trend noted for TNM
progression and the type of PET camera used. Despite the use of
a validated and standardized protocol [10] to minimize the vari-
ability for both cameras, the spatial resolution of the integrated
PET/CT scanner is higher at the visual interpretation settings. This
could explain some of the differences in the detectability of small
tumour lesions. Furthermore, additional information of the CT-
images will also increase the visualization of both regional lymph
nodes and distant metastases [17,18]. However, in the current
study, the CT images were available for both the diagnostic and
the therapeutic scans, in comparison with PET images in the case
of possible TNM progression. These ﬁndings underline the impor-tance of the use of ‘state of the art’ techniques and PET scanners
to prevent the missing of relevant tumour lesions.
The current study revealed newly detected distant metastases
in six patients (13%), which developed within 49 days. Conse-
quently, the treatment intent changed from curative to palliative
intent since metastatic disease implies that curative treatment
was no longer possible [19]. A curatively intended treatment, con-
sisting of neo-adjuvant chemoradiation followed by a surgical
resection, is very intense with the subsequent risk of (post-)opera-
tive morbidity and/or mortality, and should therefore be prevented
in patients that cannot be cured. Therefore, for the detection of
interval metastases, it remains important to reevaluate the M-
stage before surgical resection.
Newly diagnosed pathologic lymph nodes were found in eight
patients in the current study. Accurate identiﬁcation of regional
pathologic lymph nodes, and thus adequate inclusion in the gross
tumour volume (GTV) in order to ensure optimal dose coverage,
is essential for the successful radiotherapy. A treatment plan based
on the diagnostic PET information would have missed these newly
involved lymph nodes as detected on the therapeutic PET, which
might result in a geographic miss [19–22] and might lead to recur-
rence or residual tumour [23]. Given the rapid progression found in
the study, it is important to minimize the time between the rele-
vant imaging and start of the radiotherapy.
FDG-PET has some limitations regarding its use for the detection
of regional lymphnodemetastases. Nonspeciﬁc inﬂammation in the
mediastinummay result in a false-positive uptake of FDGon the PET
images. This seemed the case in two patients in which suspected
lymphnodes at the baseline PETwere no longer visible at the second
PET, suggesting temporarily inﬂammatory involvement. Potentially,
this ﬂaw can be avoided by including late time imaging in the proto-
col, as it has been shown that in time the uptake in inﬂammatory le-
sions tends to decline, whereas in most tumours the uptake is still
rising after one hour after the injection [24,25]. Furthermore, the
spatial resolution of FDG-PET is limited. Luketisch et al. [26] stated
that small regional lymph node metastases with mean greatest
dimensions ranging from 2 to 10 mm could not be detected by
FDG-PET, while Kato et al. [27] found a threshold size of 6–8 mm
for lymph node metastases. The detection of metastatic disease
FDG-PET faces the same limitations. Regional or metastatic disease
could already be present for quite some time before it becomes vis-
ible. However, the results of the current study suggest rather fast
visualization and thus the progression of oesophageal cancer.
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progression which were signiﬁcantly worse as compared to the
group without TNM progression. In the current study, a total of
four patients died in hospital after surgery, and one patient died
because of pulmonary complications and decompensatio cordis
within 90 days after surgical resection, which had its effect on
the survival rates. Although the causes of death between the
groups with or without TNM progression were not signiﬁcantly
different, the percentage of patients who died of post-operative
complications was slightly higher in the group with TNM progres-
sion. It seems reasonable that metastatic tumour progression
might inﬂuence the risk of post-operative complications.
The results of the current study suggest rapid oesophageal tu-
mour progression, in terms of an increased tumour length and/or
an advanced TNM-stage. Therefore, the interval between relevant
imaging and start of the radiotherapy should be minimized, includ-
ing re-evaluation if the start of the treatment is delayed. Further-
more, to prevent the miss of tumour lesions, ‘state of the art’ PET
scanners should be used with high spatial resolution.
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